Related Experiment Videos
Telomerase activity as a prognostic factor in neuroblastomas.
C J Streutker1, P Thorner, N Fabricius
1Department of Laboratory Medicine and Pathobiology, University of Toronto, Ontario, Canada.
Summary
High telomerase activity in neuroblastoma tumors correlates with poor prognosis and aggressive disease. Post-chemotherapy assessment of telomerase activity may further indicate patient outcomes in this common childhood cancer.
Area of Science:
- Pediatric Oncology
- Molecular Diagnostics
- Cancer Biomarkers
Background:
- Neuroblastoma is a heterogeneous extracranial solid tumor in early childhood with variable outcomes.
- Established prognostic factors include histology, MYCN copy number, 1p deletions, DNA content, and TRK-A expression.
- Emerging evidence suggests telomerase activity may also predict clinical outcome in neuroblastoma.
Purpose of the Study:
- To investigate the correlation between telomerase activity and established prognostic factors in neuroblastoma.
- To evaluate telomerase activity as a prognostic marker in untreated and post-chemotherapy neuroblastoma patients.
Main Methods:
- Assessed telomerase activity using a PCR-ELISA assay in 40 untreated neuroblastoma patients.
- Correlated telomerase activity with MYCN copy number, 1p deletions, TRK-A expression, age, stage, and outcome.
- Evaluated telomerase activity post-chemotherapy in 17 patients.
Main Results:
- Significant correlations found between high telomerase activity and MYCN copy number, 1p deletions, TRK-A expression, older age, advanced stage, and poorer outcome.
- Tumor histology was predominantly unfavorable in both high and low telomerase activity groups.
- Post-chemotherapy telomerase activity was a strong indicator: negative activity correlated with good outcomes, while persistent or post-treatment positivity indicated recurrence or death.
Conclusions:
- Telomerase activity is a significant prognostic factor for neuroblastoma.
- Assessing telomerase activity before and after chemotherapy can provide further insights into patient prognosis and treatment response.